| HOME >> BIOLOGY >> TECHNOLOGY |
Interest expense 84 - 84
Other (expense) income, net 5 - 5
Earnings before income taxes and
minority interest 96 136 232
Income tax expense 35 30(i) 65
Minority interest income (loss),
net of taxes (2) - (2)
Net earnings from continuing
operations 59 106 165
Net loss from discontinued
operations, net of taxes (2) 2(a) -
Net earnings $57 $108 $165
Diluted:
Earnings per common share -
continuing operations $0.54 $1.52
Loss per common share -
discontinued operations $(0.02) $-
Net earnings per common share -
diluted $0.52 $1.52
Weighted average shares -
diluted 108 108
Summary of Adjustment Items:
Six Months Ended
June 30,
2008 2007
(a) In order to provide investors and management a basis to evaluate the
performance of the ongoing operations, adjusted earnings exclude the
impact of discontinued operations
Accounted for as discontinued operations $- $(2)
(b) Net results from operations expected to be divested, net of minority
interest
Other revenue $(11) $(9)
Less:
Cost of sales
'/>"/>
| SOURCE Barr Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |